X
<

What Analysts Recommend for Sage Therapeutics

PART:
1 2 3 4 5
Part 4
What Analysts Recommend for Sage Therapeutics PART 4 OF 5

What to Expect from Sage Therapeutics’ Brexanolone

Sage’s Brexanolone

Sage Therapeutics’ (SAGE) Brexanolone, also known as SAGE-527, is an allosteric modulator injection under investigation. The product is based on the GABAA receptor program.

What to Expect from Sage Therapeutics&#8217; Brexanolone

Interested in SAGE? Don't miss the next report.

Receive e-mail alerts for new research on SAGE

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart shows details about the investigational drug SAGE-527.

SAGE-527

The drug SAGE-527 is under Phase III development for the treatment of postpartum depression. SAGE-527 was also being evaluated for the treatment of super-refractory status epilepticus (or SRSE) under STATUS trial. However, on September 12, 2017, the company announced the top-line results from the STATUS trial, indicating that Brexanolone didn’t meet its primary endpoints.

STATUS trial

The status trial is the abbreviated form of SAGE-547 treatment as adjunctive therapy utilized in status epilepticus. The study was a phase III, double-blind, randomized, placebo-controlled study that evaluated the safety and efficacy of the SAGE-547 injection for the treatment of SRSE.

The efficacy results showed that 43.9% of patients treated with Brexanolone were successfully weaned from the third-line agents as compared to 42.4% of patients treated with the placebo. Also, nearly 37% of patients treated with brexanolone after the double-blind period ended reported treatment response.

The safety results showed adverse effects in almost all patients, considering the complexity and severity of the disease SRSE and other ongoing treatments. However, the serious adverse events, death rates, and discontinuation of treatment due to adverse events were similar in the Brexanolone and placebo treatment groups.

To divest the company-specific risks, investors can consider ETFs like the iShares NASDAQ Biotechnology ETF (IBB), which holds 0.5% of its total assets in Sage Therapeutics (SAGE). IBB also holds 9.0% in Biogen (BIIB), 8.9% in Gilead Sciences (GILD), and 3.4% in Incyte (INCY).

X

Please select a profession that best describes you: